The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
// Michal P. Kuczma 1, 6 , Zhi-Chun Ding 1 , Tao Li 2 , Tsadik Habtetsion 1 , Tingting Chen 1 , Zhonglin Hao 1 , Locke Bryan 3 , Nagendra Singh 4 , James N. Kochenderfer 5 and Gang Zhou 1 1 Georgia Cancer Center, Augusta University, Augusta, Georgia, USA 2 Department of Oncology and Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Province, PR China 3 Hematology/Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia, USA 4 Department of Biochemistry and Molecular Biology, Augusta University, Augusta, Georgia, USA 5 Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, Maryland, USA 6 Current/Present address: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA Correspondence to: Gang Zhou, email: GZHOU@augusta.edu Keywords: antibiotics; intestinal microbiota; cyclophosphamide; chimeric antigen receptor; adoptive T-cell therapy Received: September 12, 2017 Accepted: November 26, 2017 Published: December 05, 2017 ABSTRACT In recent years the combined use of chemotherapy and immunotherapy, collectively termed chemoimmunotherapy, has emerged as a promising treatment option for patients with cancer. Antibiotics are commonly used to reduce infection-related complications in patients undergoing chemotherapy. Intriguingly, accumulating evidence has implicated gut microbiota as a critical determinant of host antitumor immune responses, raising the question as to whether the use of broad-spectrum antibiotics would invariably diminish tumor response to chemoimmunotherapies. We investigated the impact of antibiotics on the therapeutic outcomes of cyclophosphamide (CTX) chemotherapy and adoptive T-cell therapy (ACT) where CTX was used as the host-conditioning regimen in mice. We show that antibiotic prophylaxis dampened the endogenous T cell responses elicited by CTX, and reduced the efficacy of CTX against B-cell lymphoma. In the ACT setting, antibiotics administration impaired the therapeutic effects of adoptively transferred tumor-specific CD4+ T cells in mice with implanted colorectal tumors. In contrast, long-term antibiotic exposure did not affect the efficacy of ACT using CD19-targeting chimeric antigen receptor (CAR) T cells in mice with systemic B-cell lymphoma, although it correlated with prolonged CAR expression and sustained B-cell aplasia. Our study demonstrates that chemoimmunotherapies may have variable reliance on intestinal microbiota for T cell activation and function, and thus have different sensitivities to antibiotic prophylaxis. These findings may have implications for the judicial use of antibiotics in cancer patients receiving chemoimmunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“Accumulating evidence from animal studies demonstrated that the intestinal microbiota influences tumor response to a variety of cancer therapies, including cyclophosphamide (CTX) and platinum-based chemotherapy [4–6], a CpG oligodeoxynucleotide-based immunotherapeutic regimen [6], as well as immune checkpoint therapy…”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Accumulating evidence from animal studies demonstrated that the intestinal microbiota influences tumor response to a variety of cancer therapies, including cyclophosphamide (CTX) and platinum-based chemotherapy [4–6], a CpG oligodeoxynucleotide-based immunotherapeutic regimen [6], as well as immune checkpoint therapy…”
BackgroundCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“With particular relevance to CD19-CAR T-cell therapy, patients treated with CD19CAR T cells may experience prolonged B-cell aplasia and hypogammaglobulinemia [33, 34], conditions that often require intermittent antibiotics administration and immunoglobulin replacement to reduce the risk of infection [35, 36].”
BackgroundThe Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · cited 1×
“With particular relevance to CD19-CAR T-cell therapy, patients treated with CD19CAR T cells may experience prolonged B-cell aplasia and hypogammaglobulinemia [33, 34], conditions that often require intermittent antibiotics administration and immunoglobulin replacement to reduce the risk of infection [35, 36].”
BackgroundSelf-citationDaillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897 · cited 1×
“Our data are consistent with the results of two recent studies reporting that intestinal microbiota modulates the antitumor immune effects of CTX in a sarcoma mouse model [4, 5], suggesting the generality of reliance of CTX chemotherapy on gut bacteria to provoke antitumor immune responses.”
ResultPaulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · cited 4×
“Paulos et al reported in a melanoma mouse model that microbial translocation driven by TBI led to heightened dendritic cell activation which in turn augmented the function of adoptively transferred tumor-specific CD8+ T cells, and that the immunopotentiating effect of TBI was reduced in mice receiving antibiotic treat…”
BackgroundResultInfluentialMicrobiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Microbiota Modulation of Myeloid Cells in Cancer Therapy
Goldszmid, R. S., Dzutsev, A., Viaud, S., Zitvogel, L., Restifo, N. P., & Trinchieri, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0225 · Cited by 46
Cited by
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Engineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
Antibiotics for cancer treatment: A double-edged sword
Gao, Y., Shang, Q., Li, W., Guo, W., Stojadinovic, A., Mannion, C., Man, Y.-G., & Chen, T. (2020) · Journal of Cancer · doi:10.7150/jca.47470 · Cited by 253
Self-citationTinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., Krebs, M., Carter, L., Thistlethwaite, F., Graham, D., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0160 · Cited by 201
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
Metadata
- Authors
- Kuczma, M. P., Ding, Z.-C., Li, T., Habtetsion, T., Chen, T., Hao, Z., Bryan, L., Singh, N., Kochenderfer, J. N., & Zhou, G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-12-05
- Volume
- 8
- Issue
- 67
- Pages
- 111931-111942
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2774227552
- Cited by
- 75
- References
- 11
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.